, 7: The relationship between control of intraocular pressure and visual field deterioration, AGIS Investigators: The Advanced Glaucoma Intervention Study (AGIS), vol.130, pp.429-440, 2000.

, Collaborative Normal-Tension Glaucoma Study Group: The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma, Am J Ophthalmol, vol.126, pp.498-505, 1998.

A. Heijl, M. C. Leske, B. Bengtsson, L. Hyman, B. Bengtsson et al., Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial, Arch Ophthalmol, vol.120, pp.1268-1279, 2002.

M. C. Leske, A. Heijl, M. Hussein, B. Bengtsson, L. Hyman et al., Early Manifest Glaucoma Trial Group: Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial, Arch Ophthalmol, vol.121, pp.48-56, 2003.

M. A. Kass, D. K. Heuer, E. J. Higginbotham, C. A. Johnson, J. L. Keltner et al., The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma, Arch Ophthalmol, vol.120, pp.701-713, 2002.

, European Glaucoma Society Terminology and Guidelines for Glaucoma, 2008.

S. C. Patel and G. L. Spaeth, Compliance in patients prescribed eyedrops for glaucoma, Ophthalmic Surg, vol.26, pp.233-236, 1995.

R. B. Haynes, H. P. Mcdonald, and A. X. Garg, Helping patients follow prescribed treatment: clinical applications, JAMA, vol.288, pp.2880-2883, 2002.

D. L. Roter, J. A. Hall, R. Merisca, B. Nordstrom, D. Cretin et al., Effectiveness of interventions to improve patient compliance: a metaanalysis, Med Care, vol.36, pp.1138-1161, 1998.

B. Sleath, A. L. Robin, D. Covert, J. E. Byrd, G. Tudor et al., Patientreported behavior and problems in using glaucoma medications, Ophthalmology, vol.113, pp.431-436, 2006.

®. Xalacom, Summary of Product Characteristics, Electronic Medicines Compendium, vol.16, 2007.

M. Diestelhorst and L. I. Larsson, European Latanoprost Fixed Combination Study Group: A 12 week study comparing the fixed combination of latanoprost and timolol with the concomitant use of the individual components in patients with open angle glaucoma and ocular hypertension, Br J Ophthalmol, vol.88, pp.199-203, 2004.

M. Diestelhorst and L. I. Larsson, European-Canadian Latanoprost Fixed Combination Study Group: A 12-week, randomized, double-masked, multicenter study of the fixed combination of latanoprost and timolol in the evening versus the individual components, Ophthalmology, vol.113, pp.70-76, 2006.

E. J. Higginbotham, M. Diestelhorst, N. Pfeiffer, and J. F. Rouland, Alm A: The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications, Surv Ophthalmol, vol.47, issue.1, pp.133-140, 2002.

E. J. Higginbotham, R. Feldman, M. Stiles, and H. Dubiner, Fixed Combination Investigative Group: Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial, Arch Ophthalmol, vol.120, pp.915-922, 2002.

N. Pfeiffer and E. Latanoprost, Combination Study Group: A comparison of the fixed combination of latanoprost and timolol with its individual components, Graefes Arch Clin Exp Ophthalmol, vol.240, pp.893-899, 2002.

D. H. Shin, R. M. Feldman, and W. P. Sheu, Fixed Combination Latanoprost/Timolol Study Group: Efficacy and safety of the fixed combinations latanoprost/ timolol versus dorzolamide/timolol in patients with elevated intraocular pressure, Ophthalmology, vol.111, pp.276-282, 2004.

B. L. Lee, P. Gutierrez, M. Gordon, M. R. Wilson, G. A. Cioffi et al., The Glaucoma Symptom Scale. A brief index of glaucoma-specific symptoms, Arch Ophthalmol, vol.116, pp.861-866, 1998.

C. Baudouin, J. F. Rouland, J. P. Nordmann, A. Bron, and F. Pelen, Efficacy of firstor second-line latanoprost on intraocular pressure and ocular symptoms in patients with open-angle glaucoma or ocular hypertension

, J Fr Ophtalmol, vol.29, pp.615-624, 2006.

L. Ringsdorf, G. Mcgwin, and C. Owsley, Visual field defects and visionspecific health-related quality of life in African Americans and whites with glaucoma, J Glaucoma, vol.15, pp.414-418, 2006.

G. C. Rossi, C. Tinelli, G. M. Pasinetti, G. Milano, and P. E. Bianchi, Dry eye syndromerelated quality of life in glaucoma patients, Eur J Ophthalmol, vol.19, pp.572-579, 2009.

A. H. Rulo, E. L. Greve, H. C. Geijssen, and P. F. Hoyng, Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma, Ophthalmology, vol.103, pp.1276-1282, 1996.

K. Hedman and A. Alm, A pooled-data analysis of three randomized, doublemasked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol, Eur J Ophthalmol, vol.10, pp.95-104, 2000.

K. Hedman and L. I. Larsson, The effect of latanoprost compared with timolol in African-American, Asian, Caucasian, and Mexican open-angle glaucoma or ocular hypertensive patients, Surv Ophthalmol, vol.47, issue.1, pp.77-89, 2002.

A. Ang, M. A. Reddy, L. Shepstone, and D. C. Broadway, Long term effect of latanoprost on intraocular pressure in normal tension glaucoma, Br J Ophthalmol, vol.88, pp.630-634, 2004.

B. Dawson-saunders and R. B. Trapp, Basic and Clinical Biostatistics, 1990.

J. C. Tsai, C. A. Mcclure, S. E. Ramos, D. G. Schlundt, and J. W. Pichert, Compliance barriers in glaucoma: a systematic classification, J Glaucoma, vol.12, pp.393-398, 2003.

T. J. Zimmerman, S. R. Hahn, L. Gelb, H. Tan, and E. E. Kim, The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: changes in prescription patterns and patient persistence, J Ocul Pharmacol Ther, vol.25, pp.145-152, 2009.

, 12: Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma, AGIS Investigators: The Advanced Glaucoma Intervention Study, vol.134, pp.499-512, 2002.

P. R. Lichter, D. C. Musch, B. W. Gillespie, K. E. Guire, N. K. Janz et al., CIGTS Study Group: Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery, Ophthalmology, vol.108, pp.1943-1953, 2001.

D. S. Friedman, M. R. Wilson, J. M. Liebmann, R. D. Fechtner, and R. N. Weinreb, An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma, Am J Ophthalmol, vol.138, issue.3, pp.19-31, 2004.

T. Hamacher, M. Schinzel, A. Schölzel-klatt, H. M. Neff, H. Maier et al., Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies, Br J Ophthalmol, vol.88, pp.1295-1298, 2004.

S. Dunker, A. Schmucker, and H. Maier, Latanoprost/Timolol Fixed Combination Study Group: Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol, Adv Ther, vol.24, pp.376-386, 2007.

R. Mccarney, J. Warner, S. Iliffe, R. Van-haselen, M. Griffin et al., The Hawthorne Effect: a randomized, controlled trial, BMC Med Res Methodol, vol.7, p.30, 2007.

R. H. Franke and J. D. Kaul, The Hawthorne experiments: First statistical interpretation, Am Sociol Rev, vol.43, pp.623-643, 1978.

R. J. Casson, L. Liu, S. L. Graham, W. H. Morgan, J. R. Grigg et al., Efficacy and safety of bimatoprost as replacement for latanoprost in patients with glaucoma or ocular hypertension: a uniocular switch study, J Glaucoma, vol.18, pp.582-588, 2009.

M. Hatanaka, A. Reis, M. E. Sano, and R. Susanna, Additive intraocular pressure reduction effect of fixed combination of maleate timolol 0.5%/ dorzolamide 2% (Cosopt) on monotherapy with latanoprost (Xalatan) in patients with elevated intraocular pressure: a prospective, 4-week, open-label, randomized, controlled clinical trial, J Glaucoma, 2009.

G. D. Novack, R. David, P. F. Lee, M. I. Freeman, E. Duzman et al., Effect of changing medication regimens in glaucoma patients, Ophthalmologica, vol.196, pp.23-28, 1988.

K. Olander, T. J. Zimmerman, N. Downes, and J. Schoenfelder, Xalacom/ Latanoprost Study Group: Switching from latanoprost to fixedcombination latanoprost-timolol: a 21-day, randomized, doublemasked, active-control study in patients with glaucoma and ocular hypertension, Clin Ther, vol.26, pp.1619-1629, 2004.

L. E. Pillunat and L. I. Larsson, European and Canadian Latanoprost Study Group: Intraocular pressure after replacement of current dual therapy with